Previous Section
Treatment Options for Myelodysplastic Syndromes
Treatment for Low-Risk Patients with Myelodysplastic Syndromes
Because patients with low-risk myelodysplastic syndromes (MDS) usually have a better prognosis than high-risk patients, therapies that entail considerable risk (e.g., allogeneic stem cell transplantation or intensive chemotherapy) are not recommended. Patients with "low cellularity" (bone marrow contains few number of abnormal cells) are candidates for immunosuppressive therapy with anti-thymocyte globulin (ATG). Other treatments may include 5-azacytidine, decitabine, revlamid, or arsenic trioxide. As is the case with high-risk disease, clinical trials of new agents are also important.
